Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
Chatenoud
L
L
Inserm U 25, CNRS UA 122, Paris, France.
Ferran
C
C
Legendre
C
C
Kurrle
R
R
Kreis
H
H
Bach
J F
JF
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D015166:Monitoring, Immunologic; D016853:Muromonab-CD3; D010641:Phenotype; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell; D014409:Tumor Necrosis Factor-alpha